American journal of clinical oncology
Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Zaheer Qureshi, Abdur Jamil, Neehal Wali, Tobechukwu Joseph Okobi, Navkirat Kahlon
Published: 202610.1097/COC.0000000000001294
Abstract
BACKGROUND: Currently, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors combined with hormone therapy are the standard treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic…
Preview only. Read the full abstract at the source